What is the 13F Pro Quality Score for ANIP?

13F Pro ranks ANI PHARMACEUTICALS INC (ANIP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANIP's current score at https://13fpro.ai/research/ANIP (free sign-up required for the full ranking).

Where does 13F Pro source ANIP data?

All ANI PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ANI PHARMACEUTICALS INC files with the SEC under CIK 1023024. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANIP in?

ANI PHARMACEUTICALS INC (ANIP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ANIP's revenue?

Per ANI PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-05-08, the biggest revenue drivers are: Rare Disease and Brands ($128.2M, +36.3% YoY); Generics and Other ($109.2M, +6.0% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/ANIP.

What are ANIP's largest expenses?

ANI PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Cost of sales (excluding depreciation and amortization) ($93.6M, +28.1% YoY); Selling, general, and administrative ($73.7M, -3.8% YoY); Depreciation and amortization ($20.9M, -8.6% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (three months ended March 31, 2026).

How often is ANIP research updated on 13F Pro?

ANIP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ANI PHARMACEUTICALS INC(ANIP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1023024 ANIP stock profile & AI dashboard →

13F Pro Quality Score

68.6/100

Rank #408 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

88.7/100

Profitability

75.5/100

Balance Sheet

72.9/100

Earnings Quality

84.6/100

Free Cash Flow

80.4/100

Institutional Flow

1.6/100

Revenue Scale

46.9/100

Dilution Risk

28.1/100

ANIP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ANI PHARMACEUTICALS INC (ANIP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANIP at 68.6/100 on a 32-signal composite quality model, placing it at rank #408 of 2,879 stocks — the top 25% of the AI-ranked universe. ANIP scores in the top quartile across revenue growth (88.7), earnings quality (84.6), free cash flow (80.4). Areas of concern include institutional flow (1.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ANI PHARMACEUTICALS INC reports quarterly revenue of $237.5M, net income of $29.5M, an operating margin of 16.4%. Top institutional holders of ANIP by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, Soleus Capital Management, L.P., based on the most recent SEC filings. ANIP trades on the Nasdaq exchange and files with the SEC under CIK 1023024. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANI PHARMACEUTICALS INC directly from SEC EDGAR. ANI PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 89 since 2021, currently 68.6 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

What's Driving ANIP's Business? Latest 10-Q Breakdown

AI-extracted from ANI PHARMACEUTICALS INC's 10-Q filed 2026-05-08 — Q1 2026 (three months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Total revenue: $237.5M+20.5% YoY

Rare Disease and Brands$128.2M+36.3% YoY

Cortrophin Gel grew 42% from ACTH market growth and share gains; ILUVIEN up 19.5% from commercial initiatives; Harmony Agreement upfront fee of $15M and royalties $6.5M

Generics and Other$109.2M+6.0% YoY

Generic pharmaceutical products increased $6.7M from new launches and partnered product; volumes up on vancomycin and MAS ER

Largest Expense Items

Cost of sales (excluding depreciation and amortization)$93.6M+28.1% YoY

Product mix shift, royalty-bearing product growth, raw material sourcing; one supplier represents 33% of Q1 2026 purchases

Selling, general, and administrative$73.7M-3.8% YoY

Litigation settlement received $9.0M; Alimera integration costs decreased $1.5M; offset by Rare Disease sales and marketing expansion and acute gouty arthritis team recruitment

Depreciation and amortization$20.9M-8.6% YoY

Reduction from certain definite-lived intangibles fully amortized in 2025

Research and development$10.6M+0.3% YoY

Essentially flat period-over-period

Watch Items from the Filing

Four customers represent 61% of Q1 2026 net revenues (17%, 10%, 16%, 18% individually); accounts receivable from same four customers is 73% of total receivables.
One domestic supplier represents 33% of raw material inventory purchases in Q1 2026 vs. 22% in Q1 2025; company notes single-source API qualification due to cost/time of validation.
Brands portfolio revenue declined 50.9% YoY to $12.3M; company cites net decrease in demand for certain products, indicating segment weakness.
Cortrophin Gel sales grew 42% YoY to $75.1M; company is building dedicated sales force for acute gouty arthritis indication in 2026 and expanding ophthalmology overlap strategy.
ILUVIEN expanded label approved March 2025 for NIU-PS in addition to DME; company transitioned promotional focus from YUTIQ to ILUVIEN in Q2 2025; ILUVIEN revenue up 19.5% YoY.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$237.5M

Net Income

Q1 2026

$29.5M

Free Cash Flow

Q1 2026

$52.3M

Operating Margin

Q1 2026

16.4%

ROIC

Q1 2026

4.6%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+43.8% YoY

$883.4MFY 2025

FY19 $206.5MFY22 $316.4MFY24 $614.4MFY25 $883.4M

Net Income

+522.9% YoY

$78.3MFY 2025

FY19 $6.1MFY22 $-47.9MFY24 $-18.5MFY25 $78.3M

Operating Income

+18922.8% YoY

$111.1MFY 2025

FY19 $16.4MFY22 $-35.3MFY24 $584.0KFY25 $111.1M

EPS (Diluted)

+419.2% YoY

$3.32FY 2025

FY19 $0.50FY22 $-3.05FY24 $-1.04FY25 $3.32

Total Assets

+12.1% YoY

$1.44BFY 2025

FY19 $456.8MFY22 $760.1MFY24 $1.28BFY25 $1.44B

Total Debt

-2.9% YoY

$309.1MFY 2025

FY19 $185.7MFY22 $286.5MFY24 $318.3MFY25 $309.1M

Op. Cash Flow

+189.3% YoY

$185.2MFY 2025

FY19 $45.6MFY22 $-31.2MFY24 $64.0MFY25 $185.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2019	FY 2018	FY 2017
Revenue	$883.4M +43.8%	$614.4M +94.2%	$316.4M +53.2%	$206.5M +2.5%	$201.6M +14.0%	$176.8M
Net Income	$78.3M +522.9%	$-18.5M +61.3%	$-47.9M -886.0%	$6.1M -60.7%	$15.5M +1540.0%	$-1.1M
Operating Income	$111.1M +18922.8%	$584.0K +101.7%	$-35.3M -315.8%	$16.4M -53.8%	$35.4M +24.8%	$28.3M
EPS (Diluted)	$3.32 +419.2%	$-1.04 +65.9%	$-3.05 -710.0%	$0.50 -61.5%	$1.30 +1544.4%	$-0.09
Total Assets	$1.44B +12.1%	$1.28B +69.0%	$760.1M +66.4%	$456.8M +6.1%	$430.6M +4.5%	$412.1M
Total Debt	$309.1M -2.9%	$318.3M +11.1%	$286.5M +54.3%	$185.7M +163.3%	$70.6M -46.4%	$131.6M
Operating Cash Flow	$185.2M +189.3%	$64.0M +305.2%	$-31.2M -168.4%	$45.6M -32.0%	$67.1M +70.2%	$39.4M

AI Insight: ANIP Ratio Trends

ANI Pharmaceuticals executed a dramatic turnaround with operating margin recovering from -13.8% in Q3 2024 to 16.4% in Q1 2026.

• Operating margin expanded from -13.8% in Q3 2024 to 16.4% in Q1 2026, showing consistent profitability improvement.

• ROIC recovered from -11.3% in Q3 2024 to 17.9% in Q1 2026, indicating strong capital efficiency gains.

• Debt-to-equity ratio declined from 0.79 in Q4 2024 to 0.54 in Q1 2026, strengthening balance sheet leverage.

• Net profit margin turned positive in Q1 2025 and reached 12.4% in Q1 2026 after negative territory through Q4 2024.

⚠ Operating margin softened to 16.4% in Q1 2026 from peak of 15.9% in Q3 2025, worth monitoring for sustainability.

⚠ TTM operating margin of 13.4% lags Q1 2026's 16.4%, suggesting recent quarters may face seasonal headwinds ahead.

Get alerted when ANIP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ANI PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANIP

BlackRock, Inc.
$211.3M2,747,492 sh
VANGUARD CAPITAL MANAGEMENT LLC
$63.3M823,064 sh
Soleus Capital Management, L.P.
$63.1M820,243 sh
STATE STREET CORP
$59.3M771,587 sh
TANG CAPITAL MANAGEMENT LLC
$54.4M707,500 sh
GOLDENTREE ASSET MANAGEMENT LP
$51.3M667,981 sh
CAMDEN ASSET MANAGEMENT L P /CA
$50.2M40,517,000 sh
Deep Track Capital, LP
$46.1M600,000 sh
MILLENNIUM MANAGEMENT LLC
$45.5M592,013 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$43.4M564,360 sh

Fund	Value	Shares
BlackRock, Inc.	$211.3M	2,747,492
VANGUARD CAPITAL MANAGEMENT LLC	$63.3M	823,064
Soleus Capital Management, L.P.	$63.1M	820,243
STATE STREET CORP	$59.3M	771,587
TANG CAPITAL MANAGEMENT LLC	$54.4M	707,500
GOLDENTREE ASSET MANAGEMENT LP	$51.3M	667,981
CAMDEN ASSET MANAGEMENT L P /CA	$50.2M	40,517,000
Deep Track Capital, LP	$46.1M	600,000
MILLENNIUM MANAGEMENT LLC	$45.5M	592,013
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$43.4M	564,360

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANIP on your watchlist

Track score changes the day ANI PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANIP a good stock to buy?

13F Pro's AI-powered analysis of ANI PHARMACEUTICALS INC (ANIP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIP are available on the ANIP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANIP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANI PHARMACEUTICALS INC's investment landscape.